Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q1 2022 · 10-Q
Revenue$0.00$0.00— vs Q1 2021 Net Income-$6.93M-$6.93MN/M vs Q1 2021 EPS Diluted-$1.82-$1.82N/M vs Q1 2021 Operating Income-$7,252,468N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
Free Cash Flowderived-$10,129,310N/M ended Mar 31, 2022 · filed May 16, 2022 · 46 d after period end